Related Experiment Video

Updated: May 7, 2026

Functional Assessment of BRCA1 variants using CRISPR-Mediated Base Editors
09:22

Functional Assessment of BRCA1 variants using CRISPR-Mediated Base Editors

Published on: February 28, 2021

Association between MDR1 C3435T polymorphism and risk of breast cancer

Zhaoming Wang1, Ting Wang, Jianmin Bian

  • 1The First Clinical Medical College, Nanjing Medical University, Nanjing, China.

Gene
|September 28, 2013
PubMed

Insights

The multi-drug resistance gene 1 (MDR1) C3435T polymorphism may increase breast cancer risk. This meta-analysis of 10 studies suggests variant genotypes are linked to higher susceptibility.

Area of Science:

  • Genetics
  • Oncology
  • Molecular Biology

Background:

  • The C3435T polymorphism in the multi-drug resistance gene 1 (MDR1) influences P-glycoprotein activity, a factor implicated in carcinogenesis.
  • Previous studies on the association between MDR1 C3435T polymorphism and breast cancer risk have yielded conflicting results.

Purpose of the Study:

  • To conduct a meta-analysis to precisely estimate the association between the MDR1 C3435T polymorphism and breast cancer risk.
  • To synthesize findings from existing case-control studies to provide a more conclusive understanding.

Main Methods:

  • A meta-analysis was performed on 10 case-control studies.
  • Data included 5282 breast cancer cases and 7703 controls.
  • Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to assess the strength of association.

Main Results:

  • The overall analysis indicated that variant genotypes of the MDR1 C3435T polymorphism were associated with a significantly increased risk of breast cancer.
  • Specific findings included: TT vs. CC (OR=1.45, 95% CI=1.14-1.30), TT vs. CT/CC (OR=1.13, 95% CI=1.04-1.23), and TT/CT vs. CC (OR=1.22, 95% CI=1.02-1.46).

Conclusions:

  • The MDR1 C3435T polymorphism may contribute to an individual's susceptibility to developing breast cancer.
  • These findings highlight the potential role of genetic variations in MDR1 in breast cancer etiology.
Keywords:
ABCB1ATPATP-binding cassette sub-family B gene 1Breast cancerCIHWEHardy–Weinberg equilibriumMALDI-TOF MSMDRMDR1Meta-analysisORP-glycoproteinP-gpPCRPCR-RFLPSNPTP53adenosine triphosphateconfidence intervalsmatrix-assisted laser desorption/ionization time-of-flight mass spectrometrymulti-drug resistancemulti-drug resistance gene 1odds ratiopolymerase chain reactionpolymerase chain reaction-restriction fragment length polymorphismsingle-nucleotide polymorphismtumor protein gene 53

More Related Videos

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair08:15

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair

Published on: October 6, 2014

Related Concept Videos

Mismatch Repair01:36

Mismatch Repair

Overview
Mismatch Repair01:20

Mismatch Repair

Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...